Deschatelets Pascal 4
4 · Apellis Pharmaceuticals, Inc. · Filed Apr 9, 2024
Insider Transaction Report
Form 4
Deschatelets Pascal
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-04-08$54.12/sh−64,379$3,483,966→ 1,120,711 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-08−69,107→ 37,280 totalExercise: $3.76Exp: 2026-02-07→ Common Stock (69,107 underlying) - Sale
Common Stock
2024-04-08$54.92/sh−4,728$259,639→ 1,115,983 total - Exercise/Conversion
Common Stock
2024-04-08$3.76/sh+69,107$259,842→ 1,185,090 total
Footnotes (5)
- [F1]This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
- [F2]This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
- [F3]This transaction was executed in multiple trades at prices ranging from $53.770 - $54.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $54.775 - $55.750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This stock option was granted on 02/08/2016 and is fully vested.